TNF Pharmaceuticals (TNFA) announced that it received written notice from Nasdaq on September 16, confirming that the company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550. To regain compliance with the listing rule, the company’s shares maintained the minimum bid price of $1.00 for 10 consecutive business days.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNFA:
- TNF Pharmaceuticals Secures $7M in Private Placement
- TNF Pharmaceuticals Enters Licensing Agreement with LightSolver
- PharmaCyte Biotech increases stake in TNF Pharmaceuticals by $3M
- TNF Pharmaceuticals gets rights to LightSolver tech for crypto applications
- TNF Pharmaceuticals announces $7M private placement